417 related articles for article (PubMed ID: 24465696)
1. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
2. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
4. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.
Wang W; Chen D; Zhu K
J Exp Clin Cancer Res; 2018 Feb; 37(1):37. PubMed ID: 29475441
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.
Stearns ME; Amatangelo MD; Varma D; Sell C; Goodyear SM
Am J Pathol; 2010 Dec; 177(6):3169-79. PubMed ID: 20971741
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
8. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
9. Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells.
Huang CY; Chang YJ; Wei PL; Hung CS; Wang W
PLoS One; 2021; 16(3):e0248521. PubMed ID: 33725002
[TBL] [Abstract][Full Text] [Related]
10. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
[TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
Satonaka H; Ishida K; Takai M; Koide R; Shigemasa R; Ueyama J; Ishikawa T; Hayashi K; Goto H; Wakusawa S
Anticancer Res; 2017 Nov; 37(11):6071-6077. PubMed ID: 29061787
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
13. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.
Chen YJ; Chi CW; Su WC; Huang HL
Oncotarget; 2014 Jul; 5(13):4845-54. PubMed ID: 24947784
[TBL] [Abstract][Full Text] [Related]
15. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
[TBL] [Abstract][Full Text] [Related]
16. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
[TBL] [Abstract][Full Text] [Related]
19. Duo of (-)-epigallocatechin-3-gallate and doxorubicin loaded by polydopamine coating ZIF-8 in the regulation of autophagy for chemo-photothermal synergistic therapy.
Chen X; Tong R; Liu B; Liu H; Feng X; Ding S; Lei Q; Tang G; Wu J; Fang W
Biomater Sci; 2020 Mar; 8(5):1380-1393. PubMed ID: 31916560
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
